Literature DB >> 23398659

Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a rebuttal.

L Poller, J Jespersen, S Ibrahim, A Pattison.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23398659     DOI： 10.1111/jth.12164

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  4 in total

1.  [Rivaroxaban, dabigatran and apixaban: new anticoagulants in operative urology].

Authors:  A John; M S Michel
Journal:  Urologe A       Date:  2014-06       Impact factor: 0.639

2.  [Spontaneous intraocular hemorrhage under oral anticoagulation : Apixaban in comparison to phenprocoumon].

Authors:  M Treder; M Alnawaiseh; G Wirths; A Rosentreter; N Eter
Journal:  Ophthalmologe       Date:  2018-07       Impact factor: 1.059

Review 3.  Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.

Authors:  Jonathan Douxfils; Anne Tamigniau; Bernard Chatelain; Catherine Goffinet; Jean-Michel Dogné; François Mullier
Journal:  Thromb J       Date:  2014-11-04

4.  Preventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants.

Authors:  Sarah Lessire; Lessire Sarah; Anne-Sophie Dincq; Dincq Anne-Sophie; Jonathan Douxfils; Douxfils Jonathan; Bérangère Devalet; Devalet Bérangère; Jean-Baptiste Nicolas; Nicolas Jean-Baptiste; Anne Spinewine; Spinewine Anne; Anne-Sophie Larock; Larock Anne-Sophie; Jean-Michel Dogné; Dogné Jean-Michel; Maximilien Gourdin; Gourdin Maximilien; François Mullier; Mullier François
Journal:  Biomed Res Int       Date:  2014-06-16       Impact factor: 3.411
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.